Product Information
OLOPATADINE HCL 0.2% EYE DROP is a generic product labeled by Rising Pharma Holdings Inc., priced at $2.9636 per ML under NDC 16571086125. Its NADAC has been published 58 times since Aug 27, 2025.
FDA first approved this application on Jun 16, 2020.
Strength
2 mg/mL
Manufacturer
Rising Pharma Holdings Inc.NDC
16571086125
Classification
Generic
Dosage Form
SOLUTION
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
OLOPATADINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA204620FDA Approved
6/16/2020
On Market Since
5/1/2025
Pharmacological Classes
Price Statistics
The NADAC for OLOPATADINE HCL 0.2% EYE DROP has been published 58 times since Aug 27, 2025, and over the history we have for it it has declined 18.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.9636 per ML |
|---|---|
| All-time high | $3.6822 (Oct 15, 2025) |
| All-time low | $2.9636 (Sep 23, 2026) |
| 52-week high | $3.6822 |
| 52-week low | $2.9636 |
| Median price | $3.2659 |
| Average price | $3.2890 |
| Largest weekly change | -5.1% (Dec 17, 2025) |
| Weeks tracked | 58 |
| Tracking since | Aug 27, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the olopatadine hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
olopatadine hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Histamine-1 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OLOPATADINE HCL 0.2% EYE DROP?
The current National Average Drug Acquisition Cost (NADAC) for OLOPATADINE HCL 0.2% EYE DROP, manufactured by Rising Pharma Holdings Inc., is $2.9636 per ML (NDC 16571086125), effective Sep 30, 2026.
How has the price of OLOPATADINE HCL 0.2% EYE DROP changed over time?
Over the history we have for it, the NADAC for OLOPATADINE HCL 0.2% EYE DROP has declined 18.1%. It has been tracked across 58 weekly CMS publications since Aug 27, 2025.
What are the highest and lowest recorded NADAC prices for OLOPATADINE HCL 0.2% EYE DROP?
Since Aug 27, 2025, the NADAC for OLOPATADINE HCL 0.2% EYE DROP has ranged from a low of $2.9636 (Sep 23, 2026) to a high of $3.6822 (Oct 15, 2025), with a median of $3.2659 per ML.
Are there cheaper alternatives to OLOPATADINE HCL 0.2% EYE DROP?
No other NADAC-published product currently shares the active ingredient and strength of OLOPATADINE HCL 0.2% EYE DROP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures OLOPATADINE HCL 0.2% EYE DROP?
OLOPATADINE HCL 0.2% EYE DROP (NDC 16571086125) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.